Inventor · disambiguated record
Kennett Sprogøe
Also filed as: SPROGØE KENNETT
28 granted patents·39 pending applications·103 citations·filing 2010–2025
96Inventor score
Files withASCENDIS PHARMA BONE DISEASES AS23ASCENDIS PHARMA GROWTH DISORDERS AS21ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S6ASCENDIS PHARMA AS5ASCENDIS PHARMA ONCOLOGY DIV A/S4
Top patents by PatentIndex Score
67 records- 0196US11890326B2Controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Feb 6, 2024·5 cites·11 claims
- 0296US11793861B2PTH prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Oct 24, 2023·5 cites·15 claims
- 0395US12156917B2CNP prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Granted Dec 3, 2024·2 cites·13 claims
- 0495US11918628B2Controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Granted Mar 5, 2024·4 cites·9 claims
- 0595US11857603B2PTH compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Jan 2, 2024·5 cites·12 claims
- 0693US12083182B2Controlled-release CNP agonists with increased NEP stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Granted Sep 10, 2024·3 cites·15 claims
- 0792US11759504B2PTH compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Sep 19, 2023·6 cites·12 claims
- 0891US11590207B2Dosage regimen for a controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Feb 28, 2023·9 cites·5 claims
- 0990US11389510B2Controlled-release CNP agonists with low initial NPR-B activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jul 19, 2022·5 cites·6 claims
- 1090US10960053B2PEGylated recombinant human growth hormone compoundsASCENDIS PHARMA ENDOCRINOLOGY DIV A/S·Filed 2018·Granted Mar 30, 2021·5 cites·13 claims
- 1189US2025127859A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 1289US2025268988A1PTH ProdrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2024·Application pending·0 cites
- 1388US12239689B2Controlled-release CNP agonists with low initial NPR-B activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Granted Mar 4, 2025·1 cites·10 claims
- 1488US11389511B2Controlled-release CNP agonists with reduced side-effectsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jul 19, 2022·7 cites·16 claims
- 1588US11224661B2Controlled-release CNP agonists with increased NEP stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jan 18, 2022·7 cites·13 claims
- 1687US12295989B2Controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2024·Granted May 13, 2025·0 cites·5 claims
- 1787US12214020B2PTH prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Granted Feb 4, 2025·0 cites·9 claims
- 1887US2025090671A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 1986US11564974B2Combination therapy with controlled-release CNP agonistsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jan 31, 2023·6 cites·7 claims
- 2086US2024316153A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 2185US11311604B2Controlled-release CNP agonists with low NPR-C bindingASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Apr 26, 2022·6 cites·10 claims
- 2285US10980860B2Diagnosis, prevention and treatment of diseases of the jointASCENDIS PHARMA AS·Filed 2013·Granted Apr 20, 2021·11 cites·15 claims
- 2382US2025121074A1Cnp prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 2481US2023321198A1Dosage Regimen for a Controlled-Release PTH CompoundASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Application pending·0 cites
- 2580US2024173385A1PTH Compounds with Low Peak-To-Trough RatiosASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Application pending·0 cites
- 2679US9872864B2Sustained release composition of prostacyclinSPROGØE KENNETT·Filed 2012·Granted Jan 23, 2018·6 cites·13 claims
- 2777US10729778B2Carrier-linked treprostinil prodrugsHERSEL ULRICH·Filed 2017·Granted Aug 4, 2020·1 cites·24 claims
- 2877US2022008516A1PTH ProdrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2021·Application pending·0 cites
- 2977US2025090639A1Controlled-release cnp agonists with low initial npr-b activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 3077US2025302924A1Controlled-Release PTH CompoundASCENDIS PHARMA BONE DISEASES AS·Filed 2025·Application pending·0 cites
- 3176US2025041431A1Controlled-release cnp agonists with increased nep stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 3275US9561287B2Carrier-linked treprostinil prodrugsHERSEL ULRICH·Filed 2012·Granted Feb 7, 2017·3 cites·28 claims
- 3373US12274737B2PEGylated recombinant human growth hormone compoundsASCENDIS PHARMA ENDOCRINOLOGY DIV A/S·Filed 2021·Granted Apr 15, 2025·0 cites·18 claims
- 3473US10519226B2VEGF neutralizing prodrugs for the treatment of ocular conditionsASCENDIS PHARMA OPHTHALMOLOGY DIV A/S·Filed 2013·Granted Dec 31, 2019·6 cites·21 claims
- 3573US2023116746A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 3671US2020360487A1Pth prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Application pending·0 cites
- 3771US2020376089A1Pth prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Application pending·0 cites
- 3871US2024366730A1Long-Acting Growth Hormone TreatmentASCENDIS PHARMA ENDOCRINOLOGY DIV A/S·Filed 2024·Application pending·0 cites
- 3968US2023302091A1Combination Therapy with Controlled-Release CNP AgonistsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 4067US2020360488A1Pth compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Application pending·0 cites
- 4166US2023116809A1Prevention and treatment of ocular conditionsASCENDIS PHARMA OPHTHALMOLOGY DIV A/S·Filed 2022·Application pending·0 cites
- 4266US2021069339A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2020·Application pending·0 cites
- 4363US2025032585A1Effective Doses of CNP ConjugatesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 4463US2022211817A1Controlled-release cnp agonists with low npr-c bindingASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 4562US2024382567A1Long-acting PTH compound treatmentsASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Application pending·0 cites
- 4661US2020276276A1PTH ProdrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Application pending·0 cites
- 4759US2019255183A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2019·Application pending·0 cites
- 4858US2025304647A1Use Of Long-Acting Growth Hormone For Treating Inflammation-Induced DiseasesASCENDIS PHARMA AS·Filed 2022·Application pending·0 cites
- 4957US2023364199A1Improvement of physical and mental well-being of patients with hypoparathyroidismASCENDIS PHARMA BONE DISEASES AS·Filed 2021·Application pending·0 cites
- 5053US2025295738A1Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily SomatropinASCENDIS PHARMA ENDOCRINOLOGY DIV A/S·Filed 2025·Application pending·0 cites
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Kennett Sprogøe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →